Sun Pharma's Mohali plant in Punjab receives OAI status from USFDA
The plant was inspected in August and had received a form 483 with six observations earlier08-11-2022
08-11-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Update On Mohali Facility
This is with respect to our communication dated August 13, 2022 regarding the USFDA inspection at the Company's Mohali (Punjab) facility from August 03 to August 12, 2022 and issuance of Form-483 by USFDA with 6 observations. We now wish to inform you that the Company has received a communication from the USFDA determining the inspection classification as 'Official Action Indicated' (OAI). Further, the communication states that the USFDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved and may initiate additional actions, if any, under the current Consent Decree. The Company continues to manufacture and distribute existing products for the US market, thereby not likely to have any material adverse impact on current business from the facility.08-11-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst / Institutional Investor Meeting08-11-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of the Company's Q2FY23 earnings conference call.05-11-2022
Buy Sun Pharmaceutical Industries; target of Rs 1300: Sharekhan
Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1300 in its research report dated November 02, 2022.03-11-2022
Sun Pharma Q2 cheers Street
The US formulations business grew 14% to $412 million, contributing 30% to overall revenues02-11-2022
Buy Sun Pharma; target of Rs 1240: Motilal Oswal
Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 1240 in its research report dated November 02, 2022.02-11-2022
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201502-11-2022
Q2FY23 Quarterly Result Announced for Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries announced Q2FY23 results: Q2FY23: Gross sales at Rs. 108,092 million, growth of 13.1% over Q2 last year India formulation sales at Rs. 34,600 million, up 8.5% over Q2 last year US formulation sales at US$ 412 million, growth of 14.1% over Q2 last year Global specialty sales crossed US$ 200 million, growth of 27.5% over Q2 last year Emerging Markets formulation sales at US$ 259 million, up by 6.7% over Q2 last year Rest of World formulation sales at US$ 181 million, lower by about 3.8% over Q2 last year, impacted by adverse currency movements R&D; investments at Rs. 5,710 million compared to Rs. 5,364 million for Q2FY22 EBITDA at Rs. 29,565 million (including other operating revenues), up 12.4% YoY. EBITDA margin for Q2 at 27% versus 27.3% for Q2 last year Net profit for the quarter was at Rs. 22,622 million, up by 10.5% YoY, impacted by lower other income H1FY23: Gross sales at Rs. 214,532 million, growth of 11.6% over same period last year India formulation sales at Rs. 68,471 million, up 5.4% over same period last year US formulation sales at US$ 833 million, up by 12.4% over H1 last year Emerging Markets formulation sales at US$ 504 million up by 9.5% over H1 last year Rest of World formulation sales at US$ 371 million, marginally lower by 0.6% over H1 last year EBITDA at Rs. 58,409 million (including other operating revenues) up 7.2% over H1 last year, with resulting EBITDA margin of 26.9% Net profit for H1FY23 was at Rs. 43,231 million, up 23.8% YoY. Excluding the exceptional items of H1 last year, adjusted net profit was up by 7.4% Dilip Shanghvi, Managing Director of the Company said, “For Q2, we recorded double-digit topline growth and strong margins driven by market share gain in India, sustained ramp-up of our global specialty business and growth in Emerging Markets. Global specialty business has grown by 27.5% driven by Ilumya, Cequa and Winlevi. We continue to focus on expanding our global specialty business and growing all our businesses.” Result PDF02-11-2022
Results Earnings Call for Q2FY23 of Sun Pharmaceutical Industries
Conference Call with Sun Pharmaceutical Industries Management and Analysts on Q2FY23 Performance and Outlook. Listen to the full earnings transcript.01-11-2022